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Familial autosomal dominant calcium pyrophosphate dihydrate (CPPD) chondrocalcinosis has previously been
mapped to chromosome 5p15. We have identified a mutation in the ANKH gene that segregates with the disease
in a family with this condition. ANKH encodes a putative transmembrane inorganic pyrophosphate (PPi) transport
channel. We postulate that loss of function of ANKH causes elevated extracellular PPi levels, predisposing to CPPD
crystal deposition.
Chondrocalcinosis is a common arthritic condition, af-
fecting 3% of people aged 65–69 years (Felson et al.
1989), in which calcium-containing crystals form in ar-
ticular cartilage. The crystals most commonly involved
consist of either calcium pyrophosphate dihydrate
(CPPD) or calcium hydroxyapatite. Although the heri-
tability of the condition in the general community is
unknown, many families with autosomal segregation of
CPPD chondrocalcinosis have been described, implying
a significant genetic effect. The condition is frequently
asymptomatic but may cause acute flares of arthritis,
termed “pseudogout,” or chronic degenerative joint dis-
ease. Recombination mapping in British, French, and
Argentine families with autosomal dominant CPPD
chondrocalcinosis has identified a region (CCAL2 [MIM
118600]) on chromosome 5p15 that is linked with the
disease (Doherty et al. 1991; Andrew et al. 1999).
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Loss of function of an inorganic pyrophosphate (PPi)
transporter, the ANKH gene, has been demonstrated to
cause excess calcium hydroxyapatite formation in the
ank/ank mouse (Ho et al. 2000), resulting in calcium
hydroxyapatite chondrocalcinosis and joint ankylosis. In
humans, dysfunction of the ANKH gene has been dem-
onstrated to cause a rare skeletal dysplasia, autosomal
dominant craniometaphyseal dysplasia (CMD [MIM
123000]) (Nurnberg et al. 2001; Reichenberger et al.
2001). In this condition, increased bone density and skel-
etal dysplasia arise because of abnormal mineralization
of both membranous and enchondral bone. It is pos-
tulated that lower extracellular levels of PPi due to fail-
ure of transport of PPi out of chondrocytes and/or os-
teoblasts permit excess calcium hydroxyapatite crystal
formation in both CMD and the ank/ank mouse. The
human homologue of the ANKH gene lies near the re-
gion identified by recombination mapping in the families
with autosomal dominant CPPD chondrocalcinosis de-
scribed above. Therefore, we have studied this gene to
determine whether it is responsible for the CPPD dep-
osition disease in the Argentine family of northern Italian
descent with linkage to this region as reported elsewhere
(Andrew et al. 1999). Mutation screening of the ANKH
gene was performed by direct sequencing of 16 PCR
986 Am. J. Hum. Genet. 71:985–991, 2002
Table 1
Primers for PCR Amplification of ANKH Gene Coding and Promoter Region
Sequence
SEGMENT
AMPLIFIED
FRAGMENT
LENGTH
(bp)
PRIMER(5′r3′)
Forward Reverse
Promoter 1 348 caagcccccagaccgtccccg ttctgctgacagcggctccat
Promoter 2 370 cgcccgcccctgatttcctc tctgctgccgcgaggggact
Promoter 3 267 gagcagccgcgctcggagaa gaagtcgatggctatgttgg
Exon 1 298 agtcccctcgcggcagcaga gctggaaaagtcacccttga
Exon 2 455 accctataagctacttagtg agaaacatttgataattagtg
Exon 3 407 tgacccactctgggtagagg cctgccattaagctgtacacac
Exon 4 354 tgcagtccttcactccactg cagttacacacgccagaagg
Exon 5 399 cccctgtgcttctgtcagtc ctgtctttccctgcagacatc
Exon 6 392 ggcttgtgattaacatacgaagg caccgaacgagatctttatgg
Exon 7 305 cgtgcttcgtcacctactgt ccccaacgtcacattaacct
Exon 8 316 gcccgagagacactcaacat tgcccctttacaaaaaccaa
Exon 9 398 agcaagcaggtggcagatctg agtgaaattttacatttgtg
Exon 10 300 accctggcaggaagatgag cccaaactccctgacaacat
Exon 11 320 gaagccagcagatggagaac accatccaacctggtcagtg
Exon 12-1 351 caaccaaactgcaaggaaca gccgaagtgtcatcctgact
Exon 12-2 306 agaatgaataaggcacgggacg acaacgtcaaccgtgaggcag
fragments covering the 12 exons and their exon-intron
boundaries and 500 bp of the promoter region, using
combinations of primer pairs listed in table 1. Sequenc-
ing was performed using an ABI 377 automatic se-
quencer (Applied Biosystems). In all, six SNPs were iden-
tified over the 12 exons and their intronic boundaries,
and two insertions in the promoter region up to 500 bp.
One variant, a CrT transition at 14 bp from the start
codon, segregated with disease in the family (fig. 1). This
sequence change is predicted to cause a proline-to-leu-
cine substitution at amino acid position 5. This specific
mutation was confirmed by PCR-RFLP assay using a
BstNI (New England Biolab) restriction site if the mu-
tation was found (fig. 1c). Individuals 24, 38, and 48
carry the disease haplotype and are unaffected clinically
or radiographically, but they were too young to deter-
mine their affection status with certainty (ages 17–28
years; mean age at disease onset 29 years). Individuals
3 and 19 have a phenotype indistinguishable from that
of the rest of the family but do not carry the disease
haplotype. The family of the mother of individual 3 is
also affected with chondrocalcinosis, but, as reported
elsewhere, this is not linked with chromosome 5, which
leads to the conclusion that individuals 3 and 19 rep-
resent phenocopies (Andrew et al. 1999). Individual 28
is also affected with chondrocalcinosis and carries a par-
tial disease haplotype but not the P5L mutation. Exten-
sive metabolic screening for other causes of chondro-
calcinosis has been performed, and no abnormalities
have been identified. Genotyping of multiple polymor-
phisms between D5S2114 and D5S416 revealed ho-
mozygosity at all sites, suggesting the presence of uni-
parental disomy or a microdeletion. Further studies with
this individual are ongoing. We did not observe the P5L
variant in 50 Northern Italian, 52 South American His-
panic, or 100 British white healthy controls, nor in 100
nonfamilial British white patients with CPPD chondro-
calcinosis, strongly suggesting that it is a mutation
unique to this family. Parametric linkage analysis using
the MLINK option of Vitesse 2.0 was performed
(O’Connell and Weeks 1995), assuming a disease allele
frequency of 0.001, a phenocopy rate of 0.004, and pen-
etrance of 0.9, and with an autosomal dominant disease
model, as used in a previous analysis of this pedigree
(Andrew et al. 1999). Strong linkage of the disease-caus-
ing variant was noted, with a maximum LOD score of
9.6 at recombination fraction (v) 0.0.
Mutations in the ANKH gene have been reported in
abstract form in other families with familial autosomal
dominant CPPD chondrocalcinosis. These reports sup-
port our finding that this is a true disease-causing mu-
tation (Johnson et al. 2001; Pendleton et al. 2001). Other
families with CPPD chondrocalcinosis that is not linked
to chromosome 5p have also been described, indicating
the existence of locus heterogeneity (Baldwin et al.
1995).
The entire sequence of the ANKH gene has been
shown to be highly conserved, with 82% sequence iden-
tity among the human, mouse, Xenopus, and zebrafish
sequences (Nurnberg et al. 2001). Proline at amino acid
position 5 is conserved in all these species. The precise
structure of the ANKH gene is unknown. Previous com-
puter modeling based on the hydrophobicity pattern of
the protein has suggested two alternate models with ei-
ther 10 (Ho et al. 2000) or 12 (Nurnberg et al. 2001)
transmembrane helices. The latter model suggests that
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Figure 2 Predicted transmembrane domains from different structural prediction programs. Transmembrane domains are listed in red. The
programs used were DAS, HMMTOP, MPEx, PRED-TMR, PSORTII, SOSUI, SPLIT 4.0, TM-Finder, TMAP, TMpred, and TopPred2.
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the protein forms a transmembrane channel with a six-
membered helical assembly of pairs of transmembrane
domains, with alternate domains that either contribute
to the internal channel or are exterior and interact with
the membrane bilayer (Nurnberg et al. 2001). It has been
proposed that the mutations in CMD and the ank/ank
mouse cause loss of function of the channel, resulting
in increased “leakiness” to PPi, elevating intracellular
PPi, and reducing extracellular levels. We used 11 dif-
ferent structural prediction programs to investigate the
ANKH protein (fig. 2). Although there are significant
areas of agreement between the various programs, the
level of similarity of predictions is not high, with the
number of predicted transmembrane domains varying
from 7 to 12. The TMpred program previously used to
derive the proposed 12-transmembrane domain struc-
ture (Nurnberg et al. 2001) actually gives two predic-
tions, one of which has only 10 transmembrane domains
and has an inside/outside orientation opposite that of
the 12-transmembrane domain model. Clearly, there is
much yet to be determined about the structure of this
protein.
CPPD chondrocalcinosis is associated with conditions
favoring increased serum calcium or PPi (reviewed in
Timms et al. [2002]). Patients with CPPD crystals and
chondrocalcinosis have been shown to have high syn-
ovial fluid PPi levels (Russell et al. 1970; Doherty et al.
1996). Whether variation in ANKH is a cause of “spo-
radic” chondrocalcinosis remains to be determined. We
postulate that the ANKH mutation present in this family
causes a gain of ANKH function, thus increasing extra-
cellular PPi, which combines with calcium to form CPPD
crystals and causes CPPD chondrocalcinosis. This raises
the possibility of treatment of CPPD chondrocalcinosis
by interventions aimed at affecting rate of PPi transport
by ANKH.
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